Brokerages Set iRadimed Corporation (NASDAQ:IRMD) PT at $120.00

iRadimed Corporation (NASDAQ:IRMD) has been assigned a consensus rating of “Buy” from the five brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $120.00.

A number of research firms have recently commented on IRMD. Weiss Ratings lowered shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd.

Insider Transactions at iRadimed

In related news, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $96.02, for a total transaction of $480,100.00. Following the transaction, the chief executive officer owned 2,220,000 shares of the company’s stock, valued at approximately $213,164,400. The trade was a 0.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 47,500 shares of company stock worth $4,279,303 over the last 90 days. Insiders own 34.60% of the company’s stock.

Hedge Funds Weigh In On iRadimed

Institutional investors and hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC increased its position in iRadimed by 827.1% during the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 397 shares during the period. Quarry LP bought a new position in iRadimed during the third quarter worth $40,000. CWM LLC increased its position in iRadimed by 19.5% during the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after acquiring an additional 107 shares during the period. Tower Research Capital LLC TRC boosted its stake in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares in the last quarter. Finally, USA Financial Formulas acquired a new stake in iRadimed during the fourth quarter worth $82,000. Institutional investors own 92.34% of the company’s stock.

iRadimed Stock Down 0.8%

NASDAQ:IRMD opened at $93.87 on Friday. iRadimed has a 12 month low of $55.11 and a 12 month high of $107.90. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of 51.30 and a beta of 0.91. The company’s 50 day moving average is $90.40 and its 200-day moving average is $95.87.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The company had revenue of $21.98 million for the quarter, compared to analyst estimates of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Research analysts predict that iRadimed will post 1.52 EPS for the current fiscal year.

iRadimed Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, May 29th. Investors of record on Friday, May 15th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s payout ratio is 43.72%.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.